Literature DB >> 28479165

Validation of the CHA2DS2-VASc Score in Predicting Coronary Atherosclerotic Burden and In-Hospital Mortality in Patients With Acute Coronary Syndrome.

Alparslan Kurtul1, Sadik Kadri Acikgoz2.   

Abstract

Although the CHA2DS2-VASc score has been initially recommended for the assessment of the risk of thromboembolic event in patients with atrial fibrillation, in recent years, it is used to predict adverse outcomes in various cardiovascular diseases. However, little is known about its predictive value for coronary atherosclerotic burden in patients with acute coronary syndrome (ACS). The aim of the present study is to investigate whether the CHA2DS2-VASc score could predict higher coronary atherosclerotic burden assessed by SYNTAX score (SS) in ACS. A total of 2,222 ACS patients (mean age 59.8 ± 12.7 years) who underwent coronary angiography were divided into 3 SS tertiles stratified by SS: low (≤22) (n = 1,445); intermediate (23 to 32) (n = 556); and high (≥33) (n = 221). The mean CHA2DS2-VASc score was 2.71 ± 1.51 (range 1 to 9) and CHA2DS2-VASc score was higher in patients with high SS than in those with intermediate and low SS (4.24 ± 1.49, 2.89 ± 1.49, and 2.40 ± 1.36, respectively, p <0.001). In multivariate analysis, CHA2DS2-VASc score ≥4 (odds ratio [OR] 3.048, 95% confidence interval 1.658 to 5.617, p <0.001) was an independent predictor of high SS, as well as body mass index (OR 0.929, p = 0.015), chronic total occlusion (OR 11.363, p <0.001), current smoking (OR 0.476, p = 0.026), and chronic renal disease (OR 1.828, p = 0.033). The CHA2DS2-VASc score was also an independent predictor for in-hospital mortality in multivariate Cox regression analysis. In conclusion, CHA2DS2-VASc, as a simply calculated and reliable score, is independently associated with high SS and in-hospital mortality in patients with ACS. Thus, this score provides an additional level of risk stratification regarding coronary atherosclerotic burden and prognosis beyond that provided by traditional risk factors.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28479165     DOI: 10.1016/j.amjcard.2017.03.266

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Association between chronic obstructive pulmonary disease and ventricular arrhythmia: a nationwide population-based cohort study.

Authors:  Chun-Chao Chen; Cheng-Hsin Lin; Wen-Rui Hao; Chun-Chih Chiu; Yu-Ann Fang; Ju-Chi Liu; Li-Chin Sung
Journal:  NPJ Prim Care Respir Med       Date:  2021-02-12       Impact factor: 2.871

2.  CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients.

Authors:  Ramazan Gunduz; Bekir Serhat Yildiz; Ibrahim Halil Ozdemir; Nurullah Cetin; Mehmet Burak Ozen; Eren Ozan Bakir; Su Ozgur; Ozgur Bayturan
Journal:  J Thromb Thrombolysis       Date:  2021-03-17       Impact factor: 2.300

3.  The CHA2DS2-VASc Score as an Early Predictor of Graft Failure After Coronary Artery Bypass Surgery.

Authors:  Omer Tasbulak; Anil Sahin
Journal:  Cureus       Date:  2022-03-04

4.  CHA2DS2 VASc score and brachial artery flow-mediated dilation as predictors for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Mohamed Ismail Rashed; Mohamed Ayman Saleh; Ehab Mohamed Elfekky; Ahmed Mohamed Elmahmoudy
Journal:  Egypt Heart J       Date:  2022-02-23

5.  CHA2DS2-VASC score predicts coronary artery disease progression and mortality after ventricular arrhythmia in patients with implantable cardioverter-defibrillator.

Authors:  Refik Kavsur; Marc Ulrich Becher; Welat Nassan; Alexander Sedaghat; Adem Aksoy; Jan Wilko Schrickel; Georg Nickenig; Vedat Tiyerili
Journal:  Int J Cardiol Heart Vasc       Date:  2021-05-25

6.  Relationship Between CHA2DS2-VASc Score and Right Ventricular Dysfunction in Patients With Acute Pulmonary Thromboembolism.

Authors:  Murat Gök; Alparslan Kurtul; Murat Harman; Meryem Kara; Muhammed Süleymanoglu; Ender Ornek
Journal:  Clin Appl Thromb Hemost       Date:  2018-07-11       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.